Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
guidelines
myelodysplastic syndromes
patient reported outcome
prognosis
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
18 07 2021
18 07 2021
Historique:
received:
25
05
2021
revised:
05
07
2021
accepted:
06
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
5
8
2021
Statut:
epublish
Résumé
The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients' adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS.
Identifiants
pubmed: 34300079
pii: ijerph18147629
doi: 10.3390/ijerph18147629
pmc: PMC8306017
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Mol Sci. 2019 Feb 12;20(3):
pubmed: 30759825
Leuk Res. 2011 Dec;35(12):1591-6
pubmed: 21708407
Ann Oncol. 2021 Feb;32(2):142-156
pubmed: 33221366
JAMA. 1999 Oct 20;282(15):1458-65
pubmed: 10535437
Value Health. 2021 Feb;24(2):250-267
pubmed: 33518032
Eur J Haematol. 2020 May;104(5):476-487
pubmed: 31985078
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
J Natl Compr Canc Netw. 2017 Jan;15(1):60-87
pubmed: 28040720
Blood. 2017 Aug 17;130(7):859-866
pubmed: 28694324
Ann Hematol. 2021 Feb;100(2):455-463
pubmed: 33159566
Haematologica. 2020 Sep 21;105(11):2516-2523
pubmed: 33054132
Eur J Haematol. 2013 Dec;91(6):473-82
pubmed: 24102637
Leuk Res. 2008 Jul;32(7):1049-53
pubmed: 18191202
Leukemia. 2018 Aug;32(8):1679-1696
pubmed: 29946191
Qual Life Res. 1998 May;7(4):291-300
pubmed: 9610213
Blood. 2013 Sep 26;122(13):2286-8
pubmed: 24072851
Value Health. 2018 Nov;21(11):1313-1321
pubmed: 30442279
Eur J Public Health. 2017 Aug 1;27(4):616-620
pubmed: 28013246
Blood Adv. 2020 Aug 25;4(16):4029-4044
pubmed: 32841339